ANNX•benzinga•
Annexon's Investigational Drug Shows Rapid Recovery And Durable Benefit In Rare Neurological Disorder
Summary
Annexon's tanruprubart showed significant and sustained functional gains in Guillain-Barré patients, meeting key Phase 3 trial endpoints.
Original Article
Read the full article from the original source for complete details and context.
Read Full ArticleArticle published on April 9, 2025 by benzinga